<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Avatrombopag: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Avatrombopag: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Avatrombopag: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="118186" href="/d/html/118186.html" rel="external">see "Avatrombopag: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51514728"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Doptelet</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51451153"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Colony Stimulating Factor;</li>
<li>
                        Hematopoietic Agent;</li>
<li>
                        Thrombopoietic Agent;</li>
<li>
                        Thrombopoietin Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F51471128"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not use avatrombopag to normalize platelet counts.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72a76753-7c54-4996-aa16-790dc963cebb">Chronic immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic immune thrombocytopenia:</b> Oral: <b>Note:</b> Use the lowest dose necessary to achieve platelets count ≥50,000/mm<sup>3</sup> as necessary to reduce the risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30191972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30191972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosage adjustment based on platelet count:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Avatrombopag dose levels for dose titration in chronic immune thrombocytopenia: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Dose level 6: 40 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Dose level 5: 40 mg 3 times per week <b>and</b> 20 mg/day on the other 4 days of the week.</p>
<p style="text-indent:-2em;margin-left:8em;">Dose level 4: 20 mg once daily (initial dose for all patients <b>except</b> those taking moderate or strong dual inhibitors or inducers of CYP2C9 and CYP3A4).</p>
<p style="text-indent:-2em;margin-left:8em;">Dose level 3: 20 mg 3 times per week.</p>
<p style="text-indent:-2em;margin-left:8em;">Dose level 2: 20 mg twice per week <b>or</b> 40 mg once per week.</p>
<p style="text-indent:-2em;margin-left:8em;">Dose level 1: 20 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Avatrombopag dosage adjustment in chronic immune thrombocytopenia (see above for dose levels): </i></p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &lt;50,000/mm<sup>3</sup> after ≥2 weeks of avatrombopag: Increase dose <b>one dose level</b>
<i>;</i> wait 2 weeks to reassess for subsequent dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count 200,000/mm<sup>3 </sup>to 400,000/mm<sup>3</sup>: Decrease dose <b>one dose level</b>; wait 2 weeks to reassess for subsequent dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &gt;400,000/mm<sup>3</sup>: Withhold avatrombopag and increase platelet monitoring to twice per week; when platelet count is &lt;150,000/mm<sup>3</sup>, reinitiate avatrombopag with the dose decreased <b>one dose level</b>
<i>. </i></p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &lt;50,000/mm<sup>3</sup> after 4 weeks of avatrombopag at 40 mg once daily: Discontinue avatrombopag.</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &gt;400,000/mm<sup>3</sup> after 2 weeks of avatrombopag at 20 mg once weekly: Discontinue avatrombopag.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Avatrombopag discontinuation in chronic immune thrombocytopenia: </i>Discontinue avatrombopag if the platelet count does not increase to ≥50,000/mm<sup>3</sup> after 4 weeks of therapy at the maximum dose of 40 mg once daily <b>or</b> if the platelet count is &gt;400,000/mm<sup>3</sup> after 2 weeks of therapy at 20 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46536ca6-0b08-4b84-b6e4-3d21552e8be5">Chronic liver disease-associated thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic liver disease-associated thrombocytopenia: </b>Oral: <b>Note:</b> Begin avatrombopag 10 to 13 days prior to the scheduled procedure. Patients should undergo procedure 5 to 8 days after the last avatrombopag dose. Obtain a platelet count prior to therapy administration and on the day of the procedure (to ensure adequate increase in platelet count).</p>
<p style="text-indent:-2em;margin-left:4em;">Platelet count 40,000 to &lt;50,000/mm<sup>3</sup>: 40 mg once daily for 5 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29778606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29778606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Platelet count &lt;40,000/mm<sup>3</sup>: 60 mg once daily for 5 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29778606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29778606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosage adjustment for concomitant therapy with moderate or strong dual inhibitors or inducers of CYP2C9 and CYP3A4 in chronic liver disease-associated thrombocytopenia: No dosage adjustment necessary.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed doses: </i>If a dose is missed, administer the next dose as soon as it is remembered. Do not administer 2 doses at the same time to make up for a missed dose; take the next dose at the usual time the next day. Complete all 5 days of dosing if treating chronic liver disease-associated thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F51471130"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, mild to moderate renal impairment had no clinically meaningful effects on avatrombopag pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, hemodialysis is not expected to enhance avatrombopag elimination.</p></div>
<div class="block doha drugH1Div" id="F51471131"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Mild, moderate, or severe hepatic impairment (Child Pugh classes A, B, or C or MELD score 4 to 23): There are no dosage adjustments provided in the manufacturer's labeling; however, hepatic impairment had no clinically meaningful effects on avatrombopag pharmacokinetics.</p></div>
<div class="block doe drugH1Div" id="F51471129"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F51452535"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Higher incidences reported with longer duration of use.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hemorrhage (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (26%), petechia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (3% to 28%), headache (7% to 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (19%), upper respiratory tract infection (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thromboembolism (≤7%), peripheral edema (3% to 4%), venous thromboembolism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7%), nausea (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Portal vein thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarking: Hypersensitivity: Hypersensitivity reaction (including choking sensation, facial swelling, pharyngeal edema, and swollen tongue)</p></div>
<div class="block coi drugH1Div" id="F51450985"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F51471114"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Thrombotic and thromboembolic complications with thrombopoietin receptor agonist use have occurred. Portal vein thrombosis has occurred (rarely) in patients with chronic liver disease who received avatrombopag. Arterial and venous thrombotic events have occurred in patients with chronic immune thrombocytopenia. Use with caution in patients with known risk factors for thromboembolism (eg, Factor V Leiden, prothrombin 20210A, antithrombin deficiency, protein C or S deficiency). Do not administer to patients in an attempt to normalize platelet counts. Monitor for signs/symptoms of thromboembolism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Dosage form contains lactose monohydrate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not use to normalize platelet counts in patients with chronic liver disease or chronic immune thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C9 polymorphisms: CYP2C9*2 and CYP2C9*3 loss-of-function polymorphisms result in reduced CYP2C9 enzymatic activity. In a pooled pharmacogenomic analysis, when compared to subjects wild-type for CYP2C9 (normal metabolizers), subjects heterozygous for CYP2C9 loss-of-function polymorphisms (intermediate metabolizers) experienced ~1.4-fold higher exposure, and subjects homozygous for CYP2C9 loss-of-function polymorphisms (poor metabolizers) had ~2-fold higher exposure.</p></div>
<div class="block foc drugH1Div" id="F51514729"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doptelet: 20 mg</p></div>
<div class="block geq drugH1Div" id="F51514727"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51617025"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Doptelet Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $493.93</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F51471133"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food.</p></div>
<div class="block use drugH1Div" id="F51450984"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic immune thrombocytopenia:</b> Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic liver disease-associated thrombocytopenia:</b> Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.</p></div>
<div class="block mst drugH1Div" id="F51471108"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Avatrombopag may be confused with eltrombopag, lusutrombopag</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F51502245"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F51502242"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: May increase the serum concentration of Avatrombopag. Management: For chronic immune thrombocytopenia, reduce initial avatrombopag dose to 20 mg 3 times per week. No dosage reduction needed for patients with chronic liver disease-associated thrombocytopenia using avatrombopag prior to a procedure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: May decrease the serum concentration of Avatrombopag. Management: For chronic immune thrombocytopenia, increase initial avatrombopag dose to 40 mg daily. No dosage adjustment needed for patients with chronic liver disease-associated thrombocytopenia using altrombopag prior to a procedure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Avatrombopag. Management: For chronic immune thrombocytopenia, reduce initial avatrombopag dose to 20 mg 3 times per week. No dosage reduction needed for patients with chronic liver disease-associated thrombocytopenia using altrombopag prior to a procedure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May increase the serum concentration of Avatrombopag. Management: For chronic immune thrombocytopenia, reduce initial avatrombopag dose to 20 mg 3 times per week. No dosage reduction needed for patients with chronic liver disease-associated thrombocytopenia using altrombopag prior to a procedure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Avatrombopag. Management: For chronic immune thrombocytopenia, increase initial avatrombopag dose to 40 mg daily. No dosage adjustment needed for patients with chronic liver disease-associated thrombocytopenia using altrombopag prior to a procedure.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F51471112"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on findings from animal reproduction studies, in utero exposure to avatrombopag may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Thrombopoietin (TPO) receptor agonists are not currently recommended to treat immune thrombocytopenia during pregnancy except in very serious cases. If a TPO receptor agonist is needed, an agent other than avatrombopag is preferred (Provan 2019).</p></div>
<div class="block brc drugH1Div" id="F51471113"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if avatrombopag is present in breast milk. Due to the potential for serious adverse events in the breastfed infant, the manufacturer does not recommend breastfeeding during chronic therapy or for ≥2 weeks after the last avatrombopag dose. If receiving avatrombopag for brief periods (eg, prior to an invasive procedure), lactating females should pump and discard breast milk during treatment and for ≥2 weeks after the last avatrombopag dose.</p></div>
<div class="block mop drugH1Div" id="F51471135"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic immune thrombocytopenia:</b> Platelet count weekly initially until stabilized at ≥50,000/mm<sup>3 </sup>then monthly thereafter. Obtain platelet count weekly for ≥4 weeks following discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic liver disease-associated thrombocytopenia: </b>Platelet count prior to therapy initiation and on the day of the scheduled procedure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>All patients:</b> Monitor for signs/symptoms of thromboembolism. Monitor adherence.</p></div>
<div class="block pha drugH1Div" id="F51471117"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in an increased platelet production. Avatrombopag does not compete with TPO for binding at the TPO receptor and has an additive effect with TPO on platelet production.</p></div>
<div class="block phk drugH1Div" id="F51471118"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Platelet count increase: 3 to 5 days after therapy initiation; Peak effect: after 10 to 13 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Platelet count steadily declines within 7 days of procedure (Terrault 2018); Posttreatment: platelet count gradually returns to baseline values.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~180 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;96% to human plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; primarily by CYP2C9 and CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~19 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 5 to 6 hours; delayed up to 2 hours when administered with a high-fat or low-fat meal (compared to fasting).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (88%; 34% as unchanged drug); urine (6%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F53415143"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Avalet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Doptelet</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AkaRx.1">
<a name="AkaRx.1"></a>Doptelet (avatrombopag) [prescribing information]. Durham, NC: AkaRx Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dova.1">
<a name="Dova.1"></a>Doptelet (avatrombopag) [prescribing information]. Durham, NC: Dova Pharmaceuticals Inc; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30191972">
<a name="30191972"></a>Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. <i>Br J Haematol</i>. 2018;183(3):479-490. doi:10.1111/bjh.15573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avatrombopag-drug-information/abstract-text/30191972/pubmed" id="30191972" target="_blank">30191972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770441">
<a name="31770441"></a>Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avatrombopag-drug-information/abstract-text/31770441/pubmed" id="31770441" target="_blank">31770441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29778606">
<a name="29778606"></a>Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia [published online May 17, 2018]. <i>Gastroenterology. </i>doi: 10.1053/j.gastro.2018.05.025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avatrombopag-drug-information/abstract-text/29778606/pubmed" id="29778606" target="_blank">29778606</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 117929 Version 57.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
